Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients

Anaplastic lymphoma kinase (A LK ) translocation is a rare driver mutation in lung cancer. This study was aimed to report on the efficacy of lorlatinib in real-world practice and to evaluate the impact of prior ALK inhibitor treatments. We retrospectively evaluated patients with ALK -positive non–small cell lung cancer (NSCLC) treated with lorlatinib regarding its efficacy, the impact of prior ALK inhibitor treatments and the adverse events, in...